OptimizeRx Corporation (OPRX)
NASDAQ: OPRX · Real-Time Price · USD
5.12
+0.22 (4.49%)
At close: Jun 26, 2026, 4:00 PM EDT
5.16
+0.04 (0.78%)
Pre-market: Jun 29, 2026, 8:46 AM EDT

Company Description

OptimizeRx Corporation operates as a digital healthcare technology company.

It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail.

The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.

The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

OptimizeRx Corporation
OptimizeRx logo
Country United States
Founded 2006
Industry Health Information Services
Sector Healthcare
Employees 133
CEO Stephen Silvestro

Contact Details

Address:
260 Charles Street, Suite 302
Waltham, Massachusetts 02453
United States
Phone 248 651 6568
Website optimizerx.com

Stock Details

Ticker Symbol OPRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001448431
CUSIP Number 68401U102
ISIN Number US68401U2042
Employer ID 26-1265381
SIC Code 7389

Key Executives

Name Position
Stephen L. Silvestro Chief Executive Officer and Director
Edward Stelmakh C.M.A., M.B.A. Chief Financial and Strategic Officer
Brendan Merrell Chief Operating Officer
Marion K Odence-Ford Chief Legal and Administrative Officer
Maira Alejandra Media Relations Manager
Andrew Jacob D'Silva Chief Business Officer
Dr. Doug Besch Chief Product Officer and Chief Technology Officer
Heather Favazza Controller
Sheryl Kearney Human Resources Manager

Latest SEC Filings

Date Type Title
Jun 12, 2026 8-K Current Report
Jun 5, 2026 8-K Current Report
Jun 1, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 13, 2026 10-Q Quarterly Report
May 12, 2026 8-K Current Report
Apr 30, 2026 ARS Filing
Apr 30, 2026 DEF 14A Other definitive proxy statements
Apr 9, 2026 8-K Current Report
Mar 30, 2026 8-K Current Report
Mar 27, 2026 SCHEDULE 13G/A Filing